Newly developed PPAR-α agonist (R)-K-13675 inhibits the secretion of inflammatory markers without affecting cell proliferation or tube formation

Atherosclerosis

Volumn 203, Issue 1, 2009, Pages 75-81

  Kitajima, Ken ^a   Miura, Shin ichiro ^a   Mastuo, Yoshino ^a   Uehara, Yoshinari ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell proliferation; Inflammatory markers; PPAR agonist; Subtype selectivity; Tube formation

Indexed keywords

AUTACOID; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; K 13675; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; RANTES; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CELL PROLIFERATION; CULTURE MEDIUM; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN SECRETION;

ATHEROSCLEROSIS; BENZOXAZOLES; BIOLOGICAL TRANSPORT; BUTYRIC ACIDS; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CCL5; COLLAGEN; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-6; LAMININ; NF-KAPPA B; PPAR ALPHA; PROTEOGLYCANS;

EID: 60649100215     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.05.055     Document Type: Article

References (24)

1. Seki N., Bujo H., Jiang M., et al. A potent activator of PPARalpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickening in hypercholesterolemic rabbits. Atherosclerosis 178 (2005) 1-7
2. Hsueh W.A., and Law R.E. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21 (2001) 1891-1895
3. Zandbergen F., and Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 1771 (2007) 972-982
4. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
5. Ichihara S., Obata K., Yamada Y., et al. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 41 (2006) 318-329
6. Gawaz M., Brand K., Dickfeld T., et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 148 (2000) 75-85
7. Sheikine Y., and Hansson G.K. Chemokines and atherosclerosis. Ann Med 36 (2004) 98-118
8. Haddy N., Sass C., Droesch S., et al. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 170 (2003) 277-283
9. Harvey E.J., and Ramji D.P. Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?. Cardiovasc Res 67 (2005) 11-20
10. Valen G., Yan Z.Q., and Hansson G.K. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 38 (2001) 307-314
11. Weisberg S.P., Hunter D., Huber R., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116 (2006) 115-124
12. Kintscher U., Lyon C., Wakino S., et al. PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. Circ Res 91 (2002) e35-44
13. Chinetti G., Lestavel S., Fruchart J.C., et al. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res 92 (2003) 212-217
14. Miura S., Fujino M., Matsuo Y., et al. High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 802-808
15. Miura S., Matsuo Y., and Saku K. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 41 (2003) 1118-1123
16. Kleinman H.K., McGarvey M.L., Hassell J.R., et al. Basement membrane complexes with biological activity. Biochemistry 25 (1986) 312-318
17. Hiuge A., Tenenbaum A., Maeda N., et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 27 (2007) 635-641
18. Nissen S.E., Nicholls S.J., Wolski K., et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 297 (2007) 1362-1373
19. Chira E.C., McMillen T.S., Wang S., et al. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis (2007)
20. Poynter M.E., and Daynes R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273 (1998) 32833-32841
21. Duval C., Chinetti G., Trottein F., et al. The role of PPARs in atherosclerosis. Trends Mol Med 8 (2002) 422-430
22. van Raalte D.H., Li M., Pritchard P.H., et al. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 21 (2004) 1531-1538
23. Sierra M.L., Beneton V., Boullay A.B., et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem 50 (2007) 685-695
24. Huang T.H., Tran V.H., Roufogalis B.D., et al. Gypenoside XLIX, a naturally occurring PPAR-alpha activator, inhibits cytokine-induced vascular cell adhesion molecule-1 expression and activity in human endothelial cells. Eur J Pharmacol 565 (2007) 158-165